BioLife Solutions, Inc. (BLFS) closed the last trading session at $22.03, gaining 3.2% over the past four weeks, but there could be plenty of upside left in the stock if short-term price targets set by Wall Street analysts are any guide. The mean price target of $31.22 indicates a 41.7% upside potential.The average comprises nine short-term price targets ranging from a low of $30 to a high of $34, with a standard deviation of $1.48. While the lowest estimate indicates an increase of 36.2% from the current p ...

BOTHELL, Wash., May 14, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (NASDAQ: BLFS), a leading developer and supplier of bioproduction products and services for the cell and gene therapy ("CGT") market, today announced the company will be participating in the following investor conferences: 22nd Annual Craig-Hallum Institutional Investor Conference May 28, 2025 Minneapolis, MN at the Renaissance Hotel Benchmark 2025 Healthcare House Call Virtual Conference May 29, 2025 Virtual Jefferies Global Life Scie ...

Shares of BioLife Solutions, Inc. (BLFS) have gained 8.2% over the past four weeks to close the last trading session at $23.89, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $31.22 indicates a potential upside of 30.7%.The mean estimate comprises nine short-term price targets with a standard deviation of $1.48. While the lowest estimate of $30 indicates a 25.6% increase from t ...

BioLife Solutions, Inc. (BLFS) came out with quarterly earnings of $0.04 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to loss of $0.19 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.06 per share when it actually produced a loss of $0.01, delivering a surprise of 83.33%.Over the last four quarters, t ...

BioLife Solutions (BLFS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Company Participants Troy Wichterman - CFORod de Greef - Chairman & CEOPaul Knight - Managing DirectorChad Wiatrowski - VP - Equity ResearchCarl Byrnes - Managing Director Conference Call Participants Matthew Stanton - AnalystThomas Flaten - Senior Research AnalystMatthew Hewitt - Senior Research AnalystYi Chen - Managing Director & Senior Analyst Operator Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to t ...

BioLife Solutions (BLFS) Q1 2025 Earnings Call May 08, 2025 04:30 PM ET Speaker0 Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter twenty twenty five Shareholder and Analyst Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. I will now turn the call over to Troy Wickerman, Chief Financial Officer of BioLife Solutions. Please go ahead. Speake ...

BOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, is announcing corrected call-in numbers for their Earnings Call this afternoon at 4:30pm ET. If you are joining, please use 1-833-630-0431 if calling from the United States or 1-412-317-1808 if dialing internationally.About BioLife SolutionsBioLife is a leading developer and suppli ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM 10-Q þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-36362 ____________________________________________________ BioLife Solutions, Inc. (Exact name of registrant as specified in i ...

3303 Monte Villa Parkway, Suite 310 | Bothell, WA 98021 USA | 866.424.6543 phone | BioLifeSolutions.com BioLife Solutions Reports First Quarter 2025 Financial Results Cell Processing revenue of $21.6 million, up 33% over Q1 2024 GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66% GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenue Conference call begins at 4:30 p.m. Eastern time today BOTHELL, Wash. (May 8, 2025) – BioLife Solutions, Inc. (Nasdaq: BLFS ...

Cell Processing revenue of $21.6 million, up 33% over Q1 2024GAAP gross margin of 63% and non-GAAP adjusted gross margin of 66%GAAP net loss of $0.4 million and non-GAAP adjusted EBITDA of $5.7 million or 24% of revenueConference call begins at 4:30 p.m. Eastern time todayBOTHELL, Wash., May 8, 2025 /PRNewswire/ -- BioLife Solutions, Inc. (Nasdaq: BLFS) ("BioLife" or the "Company"), a leading developer and supplier of cell processing tools and services for the cell and gene therapy ("CGT") market, announces ...